1038924-61-6
Name | sacubitril |
CAS | 1038924-61-6 |
Molecular Formula | C17H17NO |
Molecular Weight | 251.32 |
MOL File | 1038924-61-6.mol |
Synonyms
sacubitril
sacubitril ISO 9001:2015 REACH
(S)-5-[(biphenyl-4-yl)Methyl]pyrrolidin-2-one
(S)-5-([1,1'-biphenyl]-4-ylMethyl)pyrrolidin-2-one
2-Pyrrolidinone, 5-([1,1'-biphenyl]-4-ylmethyl)-, (5S)-
Chemical Properties
Boiling point | 473.6±24.0 °C(Predicted) |
density | 1.117±0.06 g/cm3(Predicted) |
pka | 16.31±0.40(Predicted) |
Hazard Information
Description
Sacubitril is a neprilysin
inhibitor prodrug developed by Novartis that was approved
as part of an orally administered supramolecular sodium salt
complex with the angiotensin receptor blocker (ARB) valsartan
in the U.S. and EU in 2015. Sacubitril/valsartan (also known
as LCZ-696) is a first-in-class dual angiotensin receptor
blocker neprilysin inhibitor (ARNI) marketed for the treatment
of chronic heart failure with reduced ejection fraction
(HFrEF). It represents a novel mechanistic approach to
targeting HFrEF and is the first pharmacologic agent approved
for HFrEF since 2004. Sacubitril is metabolized by enzymatic
conversion of the ethyl ester to the active diacid (LBQ-657,
structure not disclosed), which inhibits neprilysin and prevents endogenous natriuretic peptide degradation. Neprilysin
inhibitors like sacubitril are not effective as monotherapy and
need to be combined with a reninangiotensin aldosterone
system (RAAS) inhibitor such as valsartan. Notably, dual
neprilysin and angiotensin-converting enzyme (ACE) inhibition,
as in omapatrilat, was found to be associated with an
increased risk of life-threatening angioedema due to increased
bradykinin levels. In phase III clinical trials, sacubitril/
valsartan displayed a superior safety profile to enalapril, with
a 20% decrease in heart failure hospitalizations or cardiovascular
death and a 16% reduction in the risk of death from any
cause. Sacubitril/valsartan is now recommended as the standard
of care for HFrEF as an alternative to ACEs and ARBs.
Synthesis
Several routes to sacubitril, particularly to advanced
intermediates, have been published in the primary and patent
literature.23 They differ generally in their choice of chiral pool
starting material and their approach to introduction of the
second stereocenter. The industrial scale synthesis of
intermediate 47 has been reported. Accordingly, addition of the cuprate of biaryl
bromide 41 to (S)-epichlorohydrin 42 followed by subjection
to HCl provided chloropropanol 43 in 92% yield and 99% ee.
Next, a Mitsunobu reaction involving succinimide 44 followed
by treatment with refluxing HCl and NaOH generated the
corresponding aminoalcohol, which was isolated via crystallization
as the HCl salt prior to Boc protection to give N-Boc
aminoalcohol 45 in >99% ee. Alcohol 45 was then carried
through a four-step process to give acid 47 in 75% yield,
starting with oxidation of the alcohol to the corresponding
aldehyde with TEMPO/NaOCl. The organic phase was carried
forward directly into a Wittig reaction with ylide 46, generating
an |á,|?-unsaturated ester which was hydrolyzed to acid 47 with
LiOH in an ethanol/water mixture. Interestingly, a separate
patent disclosed the stereoselective hydrogenation of the
trisubstituted olefin 47, in which subjection of 47 to catalytic
[Ru(p-cymene)I2]2 and chiral phosphine ligand Mandyphos
SL-M004-1 (48) under 40 bar of hydrogen gas in warm ethanol
delivered 49 in 99:1 dr before recrystallization.
Subsequently, activation of the acid as the acid halide through the use of thionyl chloride and ethanol not only reestablished the ethyl ester but removed the Boc group, revealing a primary amine which then reacted with succinic anhydride to ultimately deliver sacubitril (V). The freebase form of sacubitril does not readily crystallize; the isolation of a number of pharmaceutically acceptable salts of sacubitril via crystallization, most preferably the calcium salt 50 or sodium salts, have been reported.
Preparation of the sacubitril/valsartan supramolecular complex (trisodium salt, hemihydrate) has been described on a kilo-scale from sacubitril calcium salt via neutralization to the freebase and subsequent complexation with valsartan in iPrOAc/ acetone. Addition of NaOH and crystallization then provided the desired trisodium salt hemihydrate.
Subsequently, activation of the acid as the acid halide through the use of thionyl chloride and ethanol not only reestablished the ethyl ester but removed the Boc group, revealing a primary amine which then reacted with succinic anhydride to ultimately deliver sacubitril (V). The freebase form of sacubitril does not readily crystallize; the isolation of a number of pharmaceutically acceptable salts of sacubitril via crystallization, most preferably the calcium salt 50 or sodium salts, have been reported.
Preparation of the sacubitril/valsartan supramolecular complex (trisodium salt, hemihydrate) has been described on a kilo-scale from sacubitril calcium salt via neutralization to the freebase and subsequent complexation with valsartan in iPrOAc/ acetone. Addition of NaOH and crystallization then provided the desired trisodium salt hemihydrate.
Supplier
Beijing HwrkChemical Technology Co., Ltd
Telephone010-89508211 18501085097
Websitehttp://www.hwrkchemical.com
Daicel Chiral Technologies (China)CO.,LTD
Telephone021-50460086-9 15921403865
Websitehttp://www.daicelchiraltech.cn/reagents/Default.aspx
Xi'an Manareco New Materials Co., Ltd.
Telephone029-02968669089-8816
Websitehttp://www.xarlm.com
ExcelChemical (Shanghai) Chemical Technology Co., Ltd.
Telephone+86 13671938079
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList15847/0.htm
Shanghai Pansopharm Technology Co., Ltd.
Telephone021-20962833 15316628753
Websitehttp://www.pansopharm.com
Dalian Wondersun Biochemical Technology Co., Ltd.
Telephone0411-88165855
Websitehttp://www.wdspharma.com
Intelligence Pharm Science(Shanghai) Co., Ltd.
Telephone021-57898186
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList16931/0.htm
Shanghai Synchem Pharma Co., ltd
Telephone21-619849051-1 18521059765
Websitehttp://www.synchem-pharma.com
Shanghai Rochi Pharmaceutical Co., Ltd.
Telephone021-38751876 15000076078
Websitehttp://www.rochipharma.com
Shanghai BLT Biological Pharmaceutical Co., Ltd.
Telephone021-20786057 18918495077
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList19189/0.htm
ChengDu TongChuangYuan Pharmaceutical Co.Ltd
Telephone028-83379370 13880556291
Websitehttp://www.tcypharm.com
Amadis Chemical Company Limited
Telephone571-89925085
Websitehttp://www.amadischem.com
Hubei Xinyuanshun Pharmaceutical Chemical Co., Ltd.
Telephone027-50664929, 13971561712
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList20057/0.htm
Jinan Baozhao Pharmaceutical Technology Co., Ltd.
Telephone0531-82371868 13210529039
Websitehttp://www.baozhaopharm.com
Shenzhen Polymeri Biochemical Technology Co., Ltd.
Telephone+86-400-002-6226 +86-13028896684;
Websitehttps://www.rrkchem.com
ANHUI WITOP BIOTECH CO., LTD
Telephone +8615255079626
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList418627/0_EN.htm
Hefei TNJ Chemical Industry Co.,Ltd.
Telephone+86-0551-65418684 +8618949823763
Websitehttps://www.tnjchem.com
sgtlifesciences pvt ltd
Telephone +8617013299288
Websitehttps://www.chemicalbook.com/manufacturer/sgtlifesciences-pvt-591/
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine